



- (51) **International Patent Classification:**
C08G 69/00 (2006.01) *A61K 31/00* (2006.01)
- (21) **International Application Number:**
PCT/US2014/022984
- (22) **International Filing Date:**
11 March 2014 (11.03.2014)
- (25) **Filing Language:** English
- (26) **Publication Language:** English
- (30) **Priority Data:**
61/790,231 15 March 2013 (15.03.2013) US
- (71) **Applicant:** GENZYME CORPORATION [US/US]; 500 Kendall Street, Cambridge, Massachusetts 02142 (US).
- (72) **Inventors:** DHAL, Pradeep; c/o Sanofi U.S., 55 Corporate Drive, Mail Code: 55A-505A, Bridgewater, New Jersey 08807 (US). YANG, Kanwen; c/o Sanofi U.S., 55 Corporate Drive, Mail Code: 55A-505A, Bridgewater, New Jersey 08807 (US). MILLER, Robert J.; c/o Sanofi U.S., 55 Corporate Drive, Mail Code: 55A-505A, Bridgewater, New Jersey 08807 (US). HOLMS-FARLEY, Stephen Randall; 20 Norfolk Road, Arlington, MA 02476 (US).
- (74) **Agents:** SZCZEPANIK, Ann Marie et al.; Sanofi U.S., 55 Corporate Drive, Mail Code: 55A - 505A, Bridgewater, New Jersey 08807 (US).

(81) **Designated States** (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JP, KE, KG, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(84) **Designated States** (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Declarations under Rule 4.17:

- as to the applicant's entitlement to claim the priority of the earlier application (Rule 4.17(iii))
- of inventorship (Rule 4.17(iv))

[Continued on next page]

(54) Title: AMINE FUNCTIONAL POLYAMIDES

Figure 1: Susceptibility of *Pseudomonas aeruginosa* Present in Biofilm of Cystic Fibrosis-Derived Human Airway Epithelial Cells of Representative Amine Functional Polyamide




Figure 1 of 1

(57) **Abstract:** Amine functional polyamides comprise amine and ammonium groups along the polymer chain. Amine functional polyamides can be used as pharmaceutical agents and in pharmaceutical compositions. The amine functional polyamides are particularly useful in the treatment or prevention of mucositis and infection, specifically oral mucositis, surgical site infection, and lung infection associated with cystic fibrosis.



Published:

— with international search report (Art. 21(3))

— before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments (Rule 48.2(h))